Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de Zipalertinib em pacientes com câncer avançado de pulmão de células não pequenas com inserções do receptor do fator de crescimento epidérmico (EGFR) Exon 20 ou outra mutação incomum. (REZILIENT2)

5 de outubro de 2026 atualizado por: Taiho Oncology, Inc.

Um estudo de coorte multicêntrico global de fase 2b aberto para avaliar a segurança e a eficácia do Zipalertinibe em pacientes com câncer de pulmão de células não pequenas localmente avançado ou metastático com inserção do Exon 20 e mutações nos receptores do fator de crescimento epidérmico incomuns/simples ou compostas.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Visão geral do estudo

Descrição detalhada

This study will evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound Epidermal Growth Factor Receptor Proteins Mutations (EGFRmts). The drug-drug interaction (DDI) substudy will assess the potential DDI effects of zipalertinib on the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates and transporter substrates and also evaluate the relationship between zipalertinib concentration and QT interval change from baseline. Additionally, dose optimization substudy will be conducted to confirm an optimized dose of zipalertinib monotherapy.

Participants will be enrolled into 1 of the 4 following cohorts:

  • Cohort A ("prior ex20ins treatment") will include participants harboring EGFR ex20ins who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20ins agent for their advanced disease (administered together or separately).
  • Cohort B ("first-line") will include participants harboring EGFR ex20ins who have not received prior treatment for advanced or metastatic disease and are not appropriate candidates for first-line doublet platinum-based chemotherapy or have refused first-line doublet platinum-based chemotherapy.
  • Cohort C ("active brain mets") will include participants harboring EGFR ex20ins or other uncommon single or compound EGFRmts and active brain metastases and/or leptomeningeal disease (LMD). Participants may or may not have had prior treatment for advanced disease.
  • Cohort D ("other uncommon EGFRmts") will include participants harboring other non-ex20ins, excluding C797S (uncommon single or compound) EGFRmts who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.

For DDI substudy, participants will be enrolled in two groups:

  • CYP Cocktail Group will receive a single dose of cocktail of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
  • Transporter Cocktail Group will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

For dose-optimization substudy, participants with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor protein ex20ins mutations (EGFRmts) will be randomized to receive zipalertinib at different doses with continuous daily dosing until any discontinuation criterion is met. Participants will be enrolled into two groups: Arm A and Arm B, in which they will receive different doses of zipalertinib.

Tipo de estudo

Intervencional

Inscrição (Estimado)

220

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Dresden, Alemanha, 01307
        • Recrutamento
        • Uniklinik Dresden
      • Giessen, Alemanha, 35392
        • Recrutamento
        • UKGM Studienzentrale
      • Regensburg, Alemanha, 93053
        • Retirado
        • UKR Innere Med II Pneumologie
    • Hassen
      • Kassel, Hassen, Alemanha, 34125
        • Recrutamento
        • Gesundheit Nordhessen Holding AG
    • New South Wales
      • Bankstown, New South Wales, Austrália, 2200
        • Recrutamento
        • Bankstown-Lidcombe Hospital
      • Saint Leonards, New South Wales, Austrália, 2065
        • Recrutamento
        • Genesis Care North Shore
    • Western Australia
      • Joondalup, Western Australia, Austrália, 6027
        • Retirado
        • Joondalup Hospital Pharmacy
      • Brampton, Canadá, L6R 3J7
        • Recrutamento
        • William Osler Health System - Brampton Civic Hospital
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Coréia do Sul, 10408
        • Retirado
        • National Cancer Center - Korea
      • Suwon, Gyeonggi-do, Coréia do Sul, 16499
        • Recrutamento
        • Ajou University Hospital
      • Suwon, Gyeonggi-do, Coréia do Sul, 16247
        • Recrutamento
        • Saint Vincent's Hospital
    • Gyeongsangnamdo [Kyongsangnam-do]
      • Jinju, Gyeongsangnamdo [Kyongsangnam-do], Coréia do Sul, 52727
        • Recrutamento
        • Gyeongsang National University Hospital
    • Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]
      • Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi], Coréia do Sul, 22332
        • Recrutamento
        • Inha University Hospital
    • Jeollanam-do
      • Hwasun-gun, Jeollanam-do, Coréia do Sul, 58128
        • Retirado
        • Chonnam National University Hwasun Hospital
    • Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 08308
        • Recrutamento
        • Korea University Guro Hospital
      • Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital
      • Soeul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 06591
        • Retirado
        • Seoul St. Mary's Hospital
      • Barcelona, Espanha, 08036
        • Recrutamento
        • Hospital Clinic de Barcelona
      • Barcelona, Espanha, 08017
        • Recrutamento
        • UOMi Clinica Mi Tres Torres
      • Barcelona, Espanha, 08023
        • Recrutamento
        • Hospital Quirónsalud Barcelona
      • Jaén, Espanha, 23007
        • Recrutamento
        • Complejo Hospitalario de Jaen
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hospital Universitario 12 de Octubre
      • Madrid, Espanha, 28040
        • Recrutamento
        • Hospital Universitario Fundación Jiménez Díaz
      • Madrid, Espanha, 28046
        • Recrutamento
        • Hospital La Paz
      • Madrid, Espanha, 28033
        • Recrutamento
        • MD Anderson Cancer Center Madrid
    • Malaga
      • Málaga, Malaga, Espanha, 29010
        • Recrutamento
        • Hospital Regional Universitario de Málaga - Hospital General
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • Retirado
        • University of Alabama at Birmingham
    • California
      • Duarte, California, Estados Unidos, 91010
        • Recrutamento
        • City of Hope - Duarte
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Beth Israel Deaconess Medical Center
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89169
        • Recrutamento
        • Comprehensive Cancer Centers of Nevada - Central Valley - Twain
    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Basking Ridge
      • Middletown, New Jersey, Estados Unidos, 07748
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Monmouth
      • Montvale, New Jersey, Estados Unidos, 07645
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Bergen
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Commack
      • Harrison, New York, Estados Unidos, 10604
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Westchester
      • Long Island City, New York, Estados Unidos, 11101
        • Recrutamento
        • MSK Cancer Center
      • Uniondale, New York, Estados Unidos, 11553
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Nassau
    • Ohio
      • Canton, Ohio, Estados Unidos, 44718
        • Recrutamento
        • Gabrail Cancer and Research Center
      • Columbus, Ohio, Estados Unidos, 43219
        • Retirado
        • Zangmeister Cancer Center
      • Toledo, Ohio, Estados Unidos, 43623
        • Retirado
        • The Toledo Clinic Cancer Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Retirado
        • SCRI Oncology Partners
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • University of Texas MD Anderson Cancer Center
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Recrutamento
        • IDS Pharmacy
      • Saint-Herblain, França, 44800
        • Recrutamento
        • Hopital Nord Laennec
    • Aslace
      • Strasbourg, Aslace, França, 67091
        • Retirado
        • Nouvel Hôpital Civil
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, França, 69008
        • Recrutamento
        • Centre Leon Berard
    • Basse-Normandie
      • Caen, Basse-Normandie, França, 14033
        • Recrutamento
        • CHU Caen Normandie
    • Limousin
      • Limoges, Limousin, França, 87042
        • Recrutamento
        • Centre Hospitalier Universitaire Limoges
    • New Aquitaine
      • Pessac, New Aquitaine, França, 33604
        • Recrutamento
        • Hopital Haut Leveque
    • Provence-Alpes-Côte d'Azur Region
      • Marseille, Provence-Alpes-Côte d'Azur Region, França, 13015
        • Recrutamento
        • Hôpital Nord de Marseille
    • Île-de-France Region
      • Boulogne-Billancourt, Île-de-France Region, França, 92100
        • Recrutamento
        • Hopital Ambroise Pare
      • Paris, Île-de-France Region, França, 75005
        • Recrutamento
        • Institut Curie
    • Hong Kong Island
      • Pok Fu Lam, Hong Kong Island, Hong Kong
        • Recrutamento
        • Queen Mary Hospital
      • Cremona, Itália, 26100
        • Recrutamento
        • Azienda Socio-Sanitaria Territoriale di Cremona
      • Milan, Itália, 20132
        • Recrutamento
        • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
      • Parma, Itália, 43126
        • Recrutamento
        • Azienda Ospedaliero-Universitaria di Parma
      • Ravenna, Itália, 48121
        • Recrutamento
        • Ospedale S. Maria delle Croci
    • Florence
      • Florence, Florence, Itália, 50134
        • Recrutamento
        • Azienda Ospedaliero - Universitaria Careggi
    • Forli-Cesena
      • Meldola, Forli-Cesena, Itália, 47014
        • Recrutamento
        • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
      • Okayama, Japão, 700-8558
        • Recrutamento
        • Okayama University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 464-8681
        • Recrutamento
        • Aichi Cancer Center
    • Chiba
      • Kashiwa-shi, Chiba, Japão, 277-8577
        • Recrutamento
        • National Cancer Center Hospital East
    • Hukuoka
      • Fukuoka, Hukuoka, Japão, 811-1395
        • Recrutamento
        • NHO Kyushu Cancer Center
    • Miyagi
      • Sendai, Miyagi, Japão, 980-0873
        • Recrutamento
        • Sendai Kousei Hospital
    • Niigata
      • Niigata, Niigata, Japão, 951-8566
        • Recrutamento
        • Niigata Cancer Center Hospital
    • Osaka
      • Sayama, Osaka, Japão, 589-8511
        • Recrutamento
        • Kindai University Hospital
    • Shizuoka
      • Sunto-gun, Shizuoka, Japão, 411-8777
        • Recrutamento
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo Ku, Tokyo, Japão, 104-0045
        • Recrutamento
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Japão, 135-8550
        • Recrutamento
        • Cancer Institute Hospital of JFCR
    • England
      • Barnet, England, Reino Unido, EN5 3DJ
        • Recrutamento
        • The Royal Free Hospital NHS Foundation Trust
      • London, England, Reino Unido, NW3 2QG
        • Recrutamento
        • Royal Free London NHS Foundation Trust
      • Manchester, England, Reino Unido, M20 4BX
        • Recrutamento
        • The Christie NHS Foundation Trust
      • Nottingham, England, Reino Unido, NG5 1PB
        • Recrutamento
        • Nottingham University Hospitals NHS Trust
      • Adana, Turquia (Türkiye), 01140
        • Recrutamento
        • Medical Park Seyhan Hastanesi
      • Edirne, Turquia (Türkiye), 22030
        • Recrutamento
        • Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi
      • Istanbul, Turquia (Türkiye), 34722
        • Recrutamento
        • Prof. Dr. Suleyman Yalcin Sehir Hastanesi
      • Istanbul, Turquia (Türkiye), 34214
        • Retirado
        • Bagcilar Medipol Mega Universite Hastanesi
    • Istanbul
      • Esenyurt, Istanbul, Turquia (Türkiye), 34517
        • Recrutamento
        • Istinye Üniversite Hastanesi Liv Hospital Bahcesehir

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Written informed consent.

  2. ≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.

  3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

    Cohort A participants:

    • Documented EGFR ex20ins status, as determined by local testing performed at a Clinical Laboratory Improvement Amendments (CLIA) certified (United States [US]) or locally certified laboratory (outside the US).

    • Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.

      i. Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008), and BLU451. Other prior ex20ins--directed treatment may be discussed with the Sponsor for eligibility assessment.

    • Participants with brain metastasis must be neurologically stable. Participants must have received central nervous system (CNS)-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening Period. Additionally, they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with a history of uncontrolled seizures or LMD are not eligible.

    Cohort B participants:

    • Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
    • Participants who have not received prior treatment for advanced or metastatic disease and who are not appropriate candidates for first-line doublet platinum-based chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment.
    • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.

    Cohort C participants:

    • Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).

    • Presence of brain metastasis(es) characterized as at least one of the following:

      • Newly diagnosed and/or progressive brain metastasis(es) measurable by Response Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected to CNS-directed therapy, AND/OR
      • LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.
    • Participants may not require other immediate CNS-directed therapy or will likely require other CNS directed anti-tumor therapy during the first cycle of study treatment, as judged by the Investigator.

    Cohort D participants:

    • Documented other uncommon single or compound EGFR non-ex20ins status (excluding C797S), as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate document.
    • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
    • Participants who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.
    • Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment. Participants may not have received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor (TKI).
  4. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

  5. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Participants with insufficient tissue may be eligible following discussion with the Sponsor.

  6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.

  7. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.

  8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female participants are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

  9. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 1 month after the last dose of study treatment.

DDI Substudy:

  1. Participant has pathologically confirmed, locally advanced or metastatic NSCLC:

    a. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendments (CLIA) certified (US) or locally certified laboratory (outside of the US) local laboratory, defined as either one of the following EGFRmts:

    • ex20ins EGFRmt OR
    • other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) OR
    • common EGFRmt (eg, ex19del or L858R)
  2. Participant has progressed on or after receiving prior standard of care (SoC) systemic therapy for their locally advanced or metastatic NSCLC disease unless:

    • Participant for whom no approved therapy with demonstrated clinical benefit is indicated or available,
    • Participant is intolerant to the available first-line (1L) SoC treatment options, OR
    • Participant has refused 1L SoC treatment options (after being appropriately informed of the treatment options, risks, and benefits).
  3. Participants with brain metastasis are eligible if they fulfill all of the criteria below:

    • Have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by brain imaging (MRI or CT scan) during the Screening Period,
    • Are on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment,
    • Are neurologically stable with no history of uncontrolled seizures.
  4. ECOG PS of 0 or 1.

Dose Optimization Substudy:

  1. Has pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

    1. Documented EGFR ex20ins status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US)
    2. Progressed on or after systemic therapy standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.

    Note: Progression on or after systemic therapy with amivantamab is permitted (eg, given as monotherapy or in combination with chemotherapy).

  2. Participants with CNS metastases are eligible if both of the following criteria are met:

    i. Measurable lesions according to RANO-BM defined as a contrast-enhancing lesion that can be accurately measured in at least one dimension, with a minimum size of 10 millimeters (mm), or at least 5 mm if MRI slice thickness is ≤ 1.5 mm ii. Previously received definitive local treatment and have stable CNS disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) OR Asymptomatic CNS metastases ≤ 2 cm in size if, in the opinion of the investigator, immediate definitive treatment is not indicated.

  3. Measurable disease per RECIST 1.1.

  4. Has archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers

  5. ECOG PS of 0 or 1.

  6. Has adequate organ function.

Exclusion Criteria:

  1. Participant is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.

  2. Has received any of the following within the specific time frame specified:

    1. Participant has received Zipalertinib (TAS6417/CLN081) at any time
    2. CNS radiotherapy (gamma knife radiotherapy is allowed) ≤ 12 weeks, thoracic radiotherapy ≤ 28 days, or other palliative radiation ≤ 14 days prior to the first dose of study
    3. Anticancer immunotherapy ≤28 days prior to the first dose of study treatment
    4. Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.
    5. Any prior treatment with an EGFR exon20ins- targeted TKI
    6. Participants with leptomeningeal CNS disease.
  3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Participants with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.

  4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.

  5. Impaired cardiac function or clinically significant cardiac disease including any of the following:

    1. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification.
    2. Serious cardiac arrhythmias requiring treatment.
    3. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
  6. Is unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).

  7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:

    1. Adequately treated basal or squamous cell carcinoma of the skin
    2. Cancer in situ of the breast or cervix
    3. Participants with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease
    4. Participants with concurrent malignancy clinically stable and not requiring tumor-directed treatment
  8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.

  9. History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.

  10. Active bleeding disorders.

  11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.

  12. Is pregnant, lactating, or planning to become pregnant.

  13. The participant is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cohort A ("prior ex20ins treatment")

Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe
Experimental: Cohort B ("first-line treatment")

Cohort B participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe
Experimental: Cohort C ("active brain mets")

Cohort C participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe
Experimental: Cohort D ("other uncommon EGFRmts").

Cohort D participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe
Experimental: DDI Substudy: CYP Cocktail Group

Participants will receive a single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe

Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.

Experimental: DDI Substudy: Transporter Cocktail Group

Participants will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe

Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

Experimental: Dose Optimization Substudy: Arm A

Participants will receive zipalertinib, orally, at Arm A dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe
Experimental: Dose Optimization Substudy: Arm B

Participants will receive zipalertinib, orally, at Arm B dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria.

Oral tablets

Outros nomes:
  • CLN-081
  • zipalertinibe

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Coortes 1-4: Taxa de resposta objetiva (ORR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: ORR Avaliado por Revisão Central Independente Cega (BICR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos

Medidas de resultados secundários

Medida de resultado
Prazo
Coorte C: Intracraniana (i) Taxa de resposta geral (iORR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coorte C: Duração intracraniana da resposta completa (IDCR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coorte C: Duração intracraniana da resposta (IDOR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Número de participantes com tratamento Eventos adversos emergentes (TEAES) Classificados de acordo com o Critério Comunal de Terminologia do National Cancer Institute para Eventos Adversos Versão 5.0 (CTCAE V5.0)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Número de participantes com mudanças clinicamente significativas nos parâmetros de laboratório clínico
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Número de participantes com mudanças clinicamente significativas nos sinais vitais
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Número de participantes com alterações clinicamente significativas nos parâmetros de eletrocardiograma (ECG)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Número de participantes com mudança na fração de ejeção do ventrículo esquerdo (LVEF) avaliado usando eletrocardiografia (ECHO) e varredura multigada (MUGA)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Taxa de controle de doenças (DCR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Duração da resposta (DOR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Sobrevivência sem progressão (PFS)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Sobrevivência geral (OS)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Coortes 1-4: Concentração plasmática mínima (CMIN) de zipalertinibe
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
DDI Substudy: Mudança da linha de base no intervalo QT corrigido para freqüência cardíaca usando o intervalo de fórmula de Fridericia (QTCF) após a administração do zipalertinibe no grupo de coquetéis do CYP
Prazo: Ciclo 1 (comprimento do ciclo = 21 dias)
Ciclo 1 (comprimento do ciclo = 21 dias)
DDI Substudy: Concentração máxima geométrica máxima plasmática (CMAX) após administração de doses múltiplas do zipalertinibe no grupo CYP e grupos de coquetéis transportadores
Prazo: Ciclo 1 (comprimento do ciclo = 21 dias)
Ciclo 1 (comprimento do ciclo = 21 dias)
DDI Substudy: área média geométrica sob curva (AUC) após a administração de doses múltiplas de zipalertinibe no grupo CYP e grupos de coquetéis transportadores
Prazo: Ciclo 1 (comprimento do ciclo = 21 dias)
Ciclo 1 (comprimento do ciclo = 21 dias)
DDI Substudy: Número de participantes com eventos adversos emergentes de tratamento (TEAES) no grupo CYP e coquetel transportador
Prazo: Ciclo 1 (comprimento do ciclo = 21 dias)
Ciclo 1 (comprimento do ciclo = 21 dias)
Subestudo de Otimização da Dose: Duração da Resposta (DoR) Avaliada pelo BICR e pelo Investigador
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: Tempo até à Resposta Avaliada pelo BICR e pelo Investigador
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: Alteração Percentual no Tamanho do Tumor desde o Basal Avaliada pelo BICR e pelo Investigador
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: DCR Avaliada por BICR e Investigador
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: SLP Avaliado por BICR e Investigador
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: Taxa de PFS de 6 Meses
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: ORR Avaliado pelo Investigador
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: Sobrevivência Global (OS)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: ORR Intracraniana (iORR) segundo os Critérios de Avaliação da Resposta em Neuro-oncologia para Metastases Cerebrais (RANO-BM)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização da Dose: Duração da Resposta Intracraniana (iDOR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: Taxa de Controlo da Doença Intracraniana (iDCR)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos
Subestudo de Otimização de Dose: Número de Participantes com Eventos Adversos (EA) e Eventos Adversos Graves (EAG)
Prazo: Até aproximadamente 2 anos
Até aproximadamente 2 anos

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de julho de 2023

Conclusão Primária (Estimado)

31 de agosto de 2028

Conclusão do estudo (Estimado)

31 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

11 de julho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de julho de 2023

Primeira postagem (Real)

1 de agosto de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever